#pharmaceutical
Total 4 articles
China's approval of Pfizer's GLP-1 weight-loss drug unlocks a massive 1.5 billion-person market. We analyze the winners, losers, and investment implications of this regulatory shift.
Pharmaceutical giants are bringing GLP-1 weight-loss medications to America's biggest advertising stage. What does this mainstream push mean for the industry?
Danish pharma giant Novo Nordisk delivered lower-than-expected 2026 guidance, signaling intensifying competition in the obesity drug market as new players challenge Ozempic and Wegovy's dominance.
PRISM by Liabooks
Place your ad in this space
[email protected]
China is no longer a pharma copycat. With $1B R&D cycles and a massive data advantage, it's building a new global innovation engine. A PRISM analysis for investors.
